Tissue Regenix Group PLC Exercise of Options and Total Voting Rights (1806P)

TIDMTRX

RNS Number : 1806P

Tissue Regenix Group PLC

16 June 2022

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")

Exercise of Options

And Total Voting Rights

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has received notification for the exercise of options to subscribe for 2,717,391 new ordinary shares in the Company ("Ordinary Shares") at an exercise price of 0.1 pence per Ordinary Share.

The 2,717,391 new Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for these new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will occur at 8:00 a.m. on 21 June 2022.

Total Voting Rights

Following the issue of the 2,717,391 new Ordinary Shares, the Company will have a total of 7,035,794,890 Ordinary Shares in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more information:

 
 Tissue Regenix Group plc                               www.tissueregenix.com 
 David Cocke, Chief Financial Officer                         Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated            Tel: +44(0)20 7710 7600 
  Adviser and Broker) 
 Ben Maddison / Nick Harland 
 
 Walbrook PR Ltd                                     Tel: +44 (0)20 7933 8780 
 Alice Woodings / Lianne Applegarth              TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle, and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRSFDFEMEESEEM

(END) Dow Jones Newswires

June 16, 2022 08:27 ET (12:27 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024